Comparative Pharmacology
Head-to-head clinical analysis: BRANCHAMIN 4 IN PLASTIC CONTAINER versus ELCYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRANCHAMIN 4 IN PLASTIC CONTAINER versus ELCYS.
BRANCHAMIN 4% IN PLASTIC CONTAINER vs ELCYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRANCHAMIN 4% is a branched-chain amino acid (BCAA) solution providing leucine, isoleucine, and valine. It serves as a substrate for protein synthesis and energy metabolism in muscle tissue, particularly during stress or starvation. BCAAs regulate protein turnover by stimulating insulin secretion and mTOR signaling, thereby promoting anabolism and reducing catabolism.
ELCYS (eltrombopag olamine) is a small molecule agonist of the thrombopoietin receptor (TPO-R) on hematopoietic stem cells and megakaryocytes, activating JAK-STAT signaling to stimulate megakaryopoiesis and platelet production.
Intravenous infusion of 500 mL to 1000 mL per day, administered at a rate not exceeding 100 mL/hour. Typical dose: 7-10 mL/kg/day.
100 mg orally three times daily
None Documented
None Documented
Branched-chain amino acids (BCAAs) have short half-lives: leucine ~0.5-2 h, isoleucine ~1-2 h, valine ~1-2 h. In hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Renal elimination of infused amino acids; negligible biliary/fecal excretion. Typically >90% of infused nitrogen is excreted renally as urea and ammonia.
Primarily renal (approx. 35-50% unchanged drug) and biliary/fecal (about 50-60% as metabolites).
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement